Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 4/20 | 0.56 |
| ▸ | ATM | Q13315 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 7/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.54 |
| ▸ | MYB | P10242 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 8/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10313468 | 0.90 | MYB (0.54) | RAD52ATMMAPTMEN1KMT2A | |
| SCHEMBL10313469 | 0.82 | MYB (0.53) | RAD52ATMMAPTMEN1KMT2A | |
| SCHEMBL10313474 | 0.80 | HPGD (0.51) | RAD52ATMMAPTMEN1KMT2A | |
| SCHEMBL10313471 | 0.80 | MYB (0.44) | RAD52ATMMAPTMEN1KMT2A | |
| SCHEMBL10313799 | 0.77 | MYB (0.50) | RAD52ATMMAPTMEN1KMT2A | |
| SCHEMBL10313472 | 0.77 | HPGD (0.50) | ATMMAPTMEN1KMT2AMYB | |
| SCHEMBL10275902 | 0.74 | NPSR1 (0.42) | MAPTMEN1KMT2AMYBNPSR1 | |
| SCHEMBL10313689 | 0.72 | MEN1 (0.41) | ATMMAPTMEN1KMT2ANPSR1 | |
| SCHEMBL8541683 | 0.71 | MYB (0.67) | MAPTMEN1KMT2AMYBHTT | |
| SCHEMBL8543444 | 0.70 | MYB (0.70) | MAPTMEN1KMT2AMYBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2011035518-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | 辽宁利锋科技开发有限公司 (CN) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | RAD52 2408/4885ATM 1770/4885MAPT 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.